Can-Fite BioPharma Ltd.

TASE:CANF Stock Report

Market Cap: ₪53.1m

Can-Fite BioPharma Future Growth

Future criteria checks 2/6

Can-Fite BioPharma is forecast to grow earnings and revenue by 47.7% and 67.2% per annum respectively while EPS is expected to grow by 171.4% per annum.

Key information

47.7%

Earnings growth rate

171.4%

EPS growth rate

Biotechs earnings growth49.5%
Revenue growth rate67.2%
Future return on equityn/a
Analyst coverage

Low

Last updated12 Nov 2024

Recent future growth updates

Recent updates

It's Unlikely That Can-Fite BioPharma Ltd.'s (TLV:CANF) CEO Will See A Huge Pay Rise This Year

Jun 19
It's Unlikely That Can-Fite BioPharma Ltd.'s (TLV:CANF) CEO Will See A Huge Pay Rise This Year

Is Can-Fite BioPharma (TLV:CANF) In A Good Position To Invest In Growth?

Jun 30
Is Can-Fite BioPharma (TLV:CANF) In A Good Position To Invest In Growth?

We're Not Very Worried About Can-Fite BioPharma's (TLV:CANF) Cash Burn Rate

Mar 08
We're Not Very Worried About Can-Fite BioPharma's (TLV:CANF) Cash Burn Rate

Is Can-Fite BioPharma (TLV:CANF) In A Good Position To Deliver On Growth Plans?

Nov 21
Is Can-Fite BioPharma (TLV:CANF) In A Good Position To Deliver On Growth Plans?

Can-Fite BioPharma (TLV:CANF) Will Have To Spend Its Cash Wisely

May 16
Can-Fite BioPharma (TLV:CANF) Will Have To Spend Its Cash Wisely

We're A Little Worried About Can-Fite BioPharma's (TLV:CANF) Cash Burn Rate

Jan 31
We're A Little Worried About Can-Fite BioPharma's (TLV:CANF) Cash Burn Rate

Earnings and Revenue Growth Forecasts

TASE:CANF - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20260-820-92
12/31/202514421213
12/31/20241-8-9-93
6/30/20241-7-7-7N/A
3/31/20241-7N/AN/AN/A
12/31/20231-8-8-8N/A
9/30/20231-9N/AN/AN/A
6/30/20231-10-10-10N/A
3/31/20231-10N/AN/AN/A
12/31/20221-10-11-11N/A
9/30/20221-14N/AN/AN/A
6/30/20221-15-12-12N/A
3/31/20221-16N/AN/AN/A
12/31/20211-15-10-10N/A
9/30/20211-12N/AN/AN/A
6/30/20211-11-7-7N/A
3/31/20211-12N/AN/AN/A
12/31/20201-15-12-12N/A
9/30/20201-13N/AN/AN/A
6/30/20202-17-14-14N/A
3/31/20202-13N/AN/AN/A
12/31/20192-13-11-11N/A
9/30/20192-11N/AN/AN/A
6/30/20194-8-8-8N/A
3/31/20193-7N/AN/AN/A
12/31/20184-7-4-4N/A
9/30/20184-5N/AN/AN/A
6/30/20182-6-5-5N/A
3/31/20181-5N/AN/AN/A
12/31/20171-6N/A-9N/A
9/30/20171-6N/AN/AN/A
6/30/20170-9N/A-9N/A
3/31/20170-7N/AN/AN/A
12/31/20160-8N/A-9N/A
9/30/20160-5N/AN/AN/A
6/30/20160-6N/A-8N/A
3/31/20160-6N/AN/AN/A
12/31/20150-6N/A-5N/A
9/30/20150-7N/AN/AN/A
6/30/20150-5N/A-5N/A
3/31/2015N/A-5N/AN/AN/A
12/31/2014N/A-6N/A-7N/A
9/30/2014N/A-7N/AN/AN/A
6/30/2014N/A-8N/A-9N/A
3/31/2014N/A-8N/AN/AN/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CANF is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CANF is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CANF is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CANF's revenue (67.2% per year) is forecast to grow faster than the IL market (2% per year).

High Growth Revenue: CANF's revenue (67.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CANF's Return on Equity is forecast to be high in 3 years time


Discover growth companies